117708-89-1

Upstream product

• 117666-29-2 (+/-)-3,6-di-O-allyl-4-O-benzyl-1,2-O-cyclohexylidene-myo-inositol 
• 112204-05-4 (+/-)-3,6-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol 
• 136986-26-0 rac-1,3,4-Tri-O-allyl-5,6-O-isopropylidene-myo-inositol 
• 98906-37-7 (3aR,4S,5S,6S,7S,7aR)-4,5,7-Tris-allyloxy-6-benzyloxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole 
• 6404-82-6 (+/-)-1,2-O-isopropylidene-myo-inositol 
• 87-89-8 D-myo-inositol 
• 98906-34-4 (±)-2,3-O-isopropylidene-1,4-di-O-allyl-6-O-benzyl-myo-inositol 
• 98906-33-3 (±)-1,4-di-O-allyl-2,3-O-isopropylidene-myo-inositol 
• 98906-32-2 (±)-1,4-di-O-allyl-2,3:5,6-di-O-isopropylidene-myo-inositol 
• 51548-88-0 (+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol 
• 98906-37-7 (±)-2,3-O-isopropylidene-1,4,5-tri-O-allyl-6-O-benzyl-myo-inositol 

Downstream Products

• 140886-97-1 C₄₂H₅₄O₁₂ 
• 140886-97-1 C₄₂H₅₄O₁₂ 
• 140886-97-1 C₄₂H₅₄O₁₂ 
• 117666-31-6 (+)-1,3,4,5-tetra-O-allyl-6-O-benzyl-myo-inositol 
• 117666-30-5 (+)-1,3,4,5-tetra-O-allyl-2,6-di-O-benzyl-myo-inositol 
• 116907-55-2 1L-1,2,4-tri-O-benzyl-3,5,6-tris-O-dibenzyloxyphosphoryl-myo-inositol 
• 115015-97-9 (-)-1L-2,6-di-O-benzyl-myo-inositol 
• 104873-76-9 2,3,6-tris-O-(phenylmethyl)-D-myo-inositol 
• 2068-89-5 D-myo-inositol 1,4,5-triphosphate 
• 104873-75-8 (-)-1D-1,4,5-tris-O-allyl-2,3,6-tris-O-benzyl-myo-inositol 
• 98925-54-3 (+)-1,3,4-tri-O-allyl-2,5,6-tri-O-benzyl-myo-inositol 
• 141040-46-2 (1R,2R,3S,4R,5S,6S)-3,4,6-Tris-allyloxy-5-benzyloxy-cyclohexane-1,2-diol 
• 141040-49-5 (1S,2S,3R,4S,5R,6R)-3,4,6-Tris-allyloxy-5-benzyloxy-cyclohexane-1,2-diol 
• 140886-99-3 Phosphorous acid dibenzyl ester (1R,2S,3S,4R,5R,6R)-2,3,6-tris-benzyloxy-4,5-bis-(bis-benzyloxy-phosphanyloxy)-cyclohexyl ester 

Relevant academic research and scientific papers

Synthesis and in vitro anticancer activity evaluation of novel bioreversible phosphate inositol derivatives

The chemistry and biology of phosphorylated inositols have become intense areas of research during the last two decades due to their involvement in various cellular signaling processes. However, the metabolic instability by phosphatases or kinases and poo

The preparation, resolution, and phosphorylation of some benzyl ethers of myo-inositol: Intermediates for the synthesis of myo-inositol phosphates of the phosphatidylinositol cycle

The syntheses of the following chiral compounds are described: 1D-2,3,6-tri-, 1D-2,4,5-tri, 1D-2,5,6-tri-, 1D-1,2,3,4-tetra, 1D-1,2,3,6-tetra-, 1D-1,2,4,5-tetra-, and 1D-2,3,5,6-tetra-0-benzyl-myo-inositol; and 1D-2,5,6-tri-0-benzyl-1-0-p-methoxybenyl- an

TOTAL SYNTHESIS OF OPTICALLY ACTIVE MYO-INOSITOL 1,4,5-TRISPHOSPHATE AND MYO-INOSITOL 1,3,4,5-TETRAKISPHOSPHATE

A convenient approach to the preparation of the title compounds illustrating selective protection, optical resolution and phosphorylation is presented.

The Allyl Group for Protection in Carbohydrate Chemistry. Part 18. Allyl and Benzyl Ethers of myo-Inositol. Intermediates for the Synthesis of myo-Inositol Triphosphates

Racemic 1,2:4,5-di-O-isopropylidene-myo-inositol was converted into racemic 1,2,4-tri-O-benzyl-myo-inositol, 1,2,4-tri-O-p-methoxybenzyl-myo-inositol and 2,4,5-tri-O-benzyl-myo-inositol using allyl groups for 'temporary' protection.The benzyl ethers are required as intermediates for the synthesis of the 'second messenger', inositol 1,4,5-triphosphate and its metabolite, inositol 1,3,4-triphosphate. 1,2,3,4-Tetra-O-benzyl-myo-inositol, and its two monoallyl and monoprop-1-enyl ethers, were also prepared as model compounds for phosphorylation studies of the vicinal 5,6-diol system which occurs in 1,2,4-tri-O-benzyl-myo-inositol.